Press Releases March 31, 2026 08:00 PM

Brookfield Infrastructure to Host First Quarter 2026 Results Conference Call

Brookfield Infrastructure announces Q1 2026 earnings conference call and webcast details

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
BIP

Brookfield Infrastructure Partners will release its first quarter 2026 results on April 29, 2026, with a conference call and webcast scheduled on the same day. The company operates global infrastructure assets across utilities, transport, midstream, and data sectors, focusing on assets with contracted and regulated revenues to ensure stable cash flows.

Brookfield Infrastructure to Host First Quarter 2026 Results Conference Call
BIP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q1 2026 financial results to be released on April 29, 2026, before market open.
  • Conference call and webcast will be held to discuss results, with pre-registration required for participation.
  • Brookfield Infrastructure operates high-quality infrastructure assets globally, serving regulated and contracted sectors such as utilities, transport, midstream, and data.

BROOKFIELD, NEWS, April 01, 2026 (GLOBE NEWSWIRE) -- Brookfield Infrastructure Partners will hold its first quarter 2026 conference call and webcast on Wednesday, April 29, 2026, at 9:00 a.m. (ET).

Results will be released that morning before 7:00 a.m. (ET) and will be available on our website at https://bip.brookfield.com.

Participants can join by conference call or webcast.

Conference Call

  • Please pre-register at: BIP2026Q1ConferenceCall
  • Upon registering, you will be emailed a dial-in number and unique PIN. This process will bypass the operator and avoid the queue.

Webcast

  • Please join and register at: BIP2026Q1Webcast

About Brookfield Infrastructure

Brookfield Infrastructure is a leading global infrastructure company that owns and operates high-quality, long-life assets in the utilities, transport, midstream and data sectors across the Americas, Asia Pacific and Europe. We are focused on assets that have contracted and regulated revenues that generate predictable and stable cash flows. Investors can access its portfolio either through Brookfield Infrastructure Partners L.P. (NYSE: BIP; TSX: BIP.UN), a Bermuda-based limited partnership, or Brookfield Infrastructure Corporation (NYSE, TSX: BIPC), a Canadian corporation. Further information is available at https://bip.brookfield.com.

Brookfield Infrastructure is the flagship listed infrastructure company of Brookfield Asset Management, a global alternative asset manager, headquartered in New York with over $1 trillion of assets under management. For more information, go to https://brookfield.com.

Contact Information

Media
John Hamlin
Director,
Communications
Tel: +44 204 557 4334
Email: [email protected] Investor Relations
Stephen Fukuda
Managing Director,
Corporate Development & Investor Relations
Tel: +1 (416) 956 5129
Email: [email protected]



Risks

  • Potential volatility in market reaction depending on Q1 2026 financial performance, which is currently unknown.
  • Economic and geopolitical factors could impact global infrastructure operations, affecting cash flows in utilities, transport, midstream, and data sectors.
  • Regulatory changes in countries where Brookfield operates could introduce operational challenges or financial impacts.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026